Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 (0) 1494 818026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+44 (0) 1494 818026

Testimonials
During the recruitment process, I felt that I was supported throughout and that there was always the opportunity to discuss options or issues with an informed individual.
Stuart, 2011

Roche's Tamiflu receives positive US regulatory opinion

27 December 2012 11:13 in Pharmaceutical Company Product News


Roche has announced that its well-established Tamiflu therapy for acute uncomplicated influenza has received US regulatory approval in an expanded indication.

The Food and Drug Administration has ratified the treatment for use among children aged two years and older, making it the only prescription oral antiviral medicine approved to treat people of all ages, from infants to elderly people.

Two open-label safety and pharmacokinetic studies conducted in 136 infants less than one year of age showed that Tamiflu delivered a similar safety and efficacy profile to that observed in older children and adults.

Dr Hal Barron, head of global product development and chief medical officer for Roche, said this new approval is important "particularly because the Centers for Disease Control advises against vaccinating infants less than six months of age".

To date, around 90 million people from more than 80 countries have received a prescription for Tamiflu to treat or prevent influenza, including more than 30 million children.

The drug was developed as part of a collaboration between Roche and Gilead Sciences.ADNFCR-8000103-ID-801512902-ADNFCR

Other news stories from 27/12/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd